Last reviewed · How we verify
PrabotulinumtoxinA for Injection
At a glance
| Generic name | PrabotulinumtoxinA for Injection |
|---|---|
| Also known as | Jeuveau |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- COVID-19
- Injection site pain
- Dysphagia
- Neck pain
- Upper Respiratory tract infection
- Neck Pain
- Headache
- Dupuytren's contracture
- Limb discomfort
- Tension headache
- Influenza like illness
- Sinusitis
Key clinical trials
- Comparison of Dry Needling and Two Botulinum Toxins for Bruxism (NA)
- Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
- BoTox Into the Sternocleidomastoid Muscles (SCM) (PHASE4)
- Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area (NA)
- Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention (PHASE2)
- Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults (PHASE2)
- Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia (PHASE2)
- A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |